Article Text

Download PDFPDF
The Inflammation-Based Glasgow Prognostic Score Predicts Survival in Patients With Cervical Cancer
  1. Stephan Polterauer, MD,
  2. Christoph Grimm, MD,
  3. Veronika Seebacher, MD,
  4. Jasmin Rahhal, MD,
  5. Clemens Tempfer, MD,
  6. Alexander Reinthaller, MD and
  7. Lukas Hefler, MD
  1. Department of Gynecology and Gynecologic Oncology, Medical University of Vienna, Austria.
  1. Address correspondence and reprint requests to Stephan Polterauer, MD, Department of Gynecology and Gynecologic Oncology Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. E-mail: stephan.polterauer{at}meduniwien.ac.at.

Abstract

Objectives: The Glasgow Prognostic Score (GPS) is known to reflect the degree of tumor-associated cachexia and inflammation and is associated with survival in various malignancies. We investigated the value of the GPS in patients with cervical cancer.

Methods: We included 244 consecutive patients with cervical cancer in our study. The pretherapeutic GPS was calculated as follows: patients with elevated C-reactive protein serum levels (>10 mg/L) and hypoalbuminemia (<35 g/L) were allocated a score of 2, and patients with 1 or no abnormal value were allocated a score of 1 or 0, respectively. The association between GPS and survival was evaluated by univariate log-rank tests and multivariate Cox regression models. The GPS was correlated with clinicopathologic parameters as shown by performing χ2 tests.

Results: In univariate analyses, GPS (P < 0.001, P < 0.001), International Federation of Gynecology and Obstetrics (FIGO) stage (P < 0.001, P < 0.001), and lymph node involvement (P < 0.001, P < 0.001), but not patients' age (P = 0.2, P = 0.07), histological grade (P = 0.08, P = 0.1), and histological type (P = 0.8, P = 0.9), were associated with disease-free and overall survival, respectively. In a multivariate analysis GPS (P = 0.03, P = 0.04), FIGO stage (P = 0.006, P = 0.006), and lymph node involvement (P = 0.003, P = 0.002), but not patients' age (P = 0.5, P = 0.5), histological grade (P = 0.7, P = 0.6), and histological type (P = 0.4, P = 0.6) were associated with disease-free and overall survival, respectively. The GPS was associated with FIGO stage (P < 0.001) and histological grade (P = 0.02).

Conclusions: The GPS can be used as an inflammation-based predictor for survival in patients with cervical cancer.

  • Cervical cancer
  • Inflammation
  • Glasgow Prognostic Score
  • Prognosis

Statistics from Altmetric.com

Footnotes

  • The authors have no conflict of interest to disclose.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.